CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer
Alessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, Laura Matteucci, Francesco De Rosa, Jenny Bulgarelli, Marcella Tazzari, Massimiliano Petrini, Emanuela Scarpi, Sara Testoni, Anna Miserocchi, Ottavia Tartagni, Chiara Zani, Maria Laura Iaia, Ilaria Toma, Massimo Giuseppe Viola, Maria Teresa Mita, Emiliano Tamburini, Laura Ridolfi
Springer Nature ·
2025-11-22
· DOI 10.1186/s12885-025-15371-7
The publisher did not provide an abstract — full text is available via the link below.
Alessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, Laura Matteucci, Francesco De Rosa, Jenny Bulgarelli et al. CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer. // BMC Cancer. – 2025. – DOI: 10.1186/s12885-025-15371-7. – URL: https://doi.org/10.1186/s12885-025-15371-7
Alessandro Passardi, Francesco Giulio Sullo, Alessandro Bittoni, Laura Matteucci, Francesco De Rosa, Jenny Bulgarelli, Marcella Tazzari, Massimiliano Petrini, Emanuela Scarpi, Sara Testoni, Anna Miserocchi, Ottavia Tartagni, Chiara Zani, Maria Laura Iaia, Ilaria Toma, Massimo Giuseppe Viola, Maria Teresa Mita, Emiliano Tamburini, & Laura Ridolfi (2025). CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer. BMC Cancer. https://doi.org/10.1186/s12885-025-15371-7
Alessandro Passardi, et al. “CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer.” BMC Cancer, 2025. doi:10.1186/s12885-025-15371-7.
@article{Passardi2025,
title = {CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer},
author = {Passardi, Alessandro and Sullo, Francesco Giulio and Bittoni, Alessandro and Matteucci, Laura and Rosa, Francesco De and Bulgarelli, Jenny and Tazzari, Marcella and Petrini, Massimiliano and Scarpi, Emanuela and Testoni, Sara and Miserocchi, Anna and Tartagni, Ottavia and Zani, Chiara and Iaia, Maria Laura and Toma, Ilaria and Viola, Massimo Giuseppe and Mita, Maria Teresa and Tamburini, Emiliano and Ridolfi, Laura},
journal = {BMC Cancer},
year = {2025},
doi = {10.1186/s12885-025-15371-7},
url = {https://doi.org/10.1186/s12885-025-15371-7}
}